Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets continue to trade firm
Thu, 28 Aug 11:30 am

After opening firm, the Indian Indices continued to trade above the dotted line during the morning trading session. Majority of the sectoral indices are witnessing buying interest, with stocks from oil and gas and capital goods sector leading the gains.

The BSE-Sensex is trading up by about 70 points while NSE-Nifty is trading up by about 21 points. The BSE Mid Cap index is trading higher by 0.10% and BSE Small Cap index is trading up by 0.54%. The rupee is trading at 60.46 to the US dollar.

Majority of Software stocks are trading in the red with Mphasis and Infosys being the top losers. As per financial daily, India's fifth largest software service company Tech Mahindra is considering various options for acquisition for both in Indian and overseas markets. Reportedly, as per the company's chairman Anand Mahindra, the company will have to make acquisitions in order to fuel growth. Historically, Tech Mahindra has remained quite active in making acquisitions. In last two financial years, the company has made seven acquisitions. Some of the known names are Satyam computer service, Hutchison global services and Comviva technologies. Through acquisitions company has also built new client base in various geographies. Tech Mahindra was trading up by 1%

Most of the Indian pharma stocks are trading weak with Indoco Remedies and Dishman pharma being the leading losers . Ranbaxy Laboratories has made an announcement that the company has received letter from competition commission of India (CCI). As per this letter, the company is required to publish details of the proposed combination between Ranbaxy and Sun pharma. Since some time, CCI is investigating over this acquisition as the regulator believes the said acquisition will result into market domination which in turn will hurt the public interest. It is believed that the acquisition can impact the prices of some essential drugs.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets continue to trade firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.